American Heart Journal
Volume 145, Issue 5 , Pages 758-767 , May 2003

Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?

  • Jamieson MacDonald Bourque, BA

      Affiliations

    • Division of Cardiology and the Division of Nuclear Medicine, Department of Internal Medicine and Department of Radiology, Duke University Medical Center, Durham, NC, USA
    • Corresponding Author InformationReprint requests: Jamieson M. Bourque, DUMC Box 3356, Durham, NC 27710, USA.
    • ,
  • Eric J Velazquez, MD

      Affiliations

    • Division of Cardiology and the Division of Nuclear Medicine, Department of Internal Medicine and Department of Radiology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Salvador Borges-Neto, MD

      Affiliations

    • Division of Cardiology and the Division of Nuclear Medicine, Department of Internal Medicine and Department of Radiology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Linda K Shaw, MS

      Affiliations

    • Division of Cardiology and the Division of Nuclear Medicine, Department of Internal Medicine and Department of Radiology, Duke University Medical Center, Durham, NC, USA
    • ,
  • David J Whellan, MD

      Affiliations

    • Division of Cardiology and the Division of Nuclear Medicine, Department of Internal Medicine and Department of Radiology, Duke University Medical Center, Durham, NC, USA
    • ,
  • Christopher M O’Connor, MD

      Affiliations

    • Division of Cardiology and the Division of Nuclear Medicine, Department of Internal Medicine and Department of Radiology, Duke University Medical Center, Durham, NC, USA

References 

  1. American Heart Association . 2001 heart and stroke statistical update. Dallas: American Heart Association; 2000;
  2. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J. 1991;121:1852–1853
  3. Rose EA, Moskowitz AJ, Packer M, et al.  The REMATCH trial (rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure). Ann Thorac Surg. 1999;67:723–730
  4. Franciosa JA, Wilen M, Ziesche S, et al.  Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831–836
  5. Fraund S, Pethig K, Franke U, et al.  Ten year survival after heart transplantation (palliative procedure or successful long term treatment?). Heart. 1999;82:47–51
  6. Cleland JG. Improving patient outcomes in heart failure (evidence and barriers). Heart. 2000;84(1 Suppl):i8–10
  7. Lee KS, Marwick TH, Cook SA, et al.  Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction (relative efficacy of medical therapy and revascularization). Circulation. 1994;90:2687–2694
  8. vom Dahl J, Eitzman DT, al Aouar ZR, et al.  Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization. Circulation. 1994;90:2356–2366
  9. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211–221
  10. Ferrari R, Ceconi C, Curello S, et al.  Left ventricular dysfunction due to the new ischemic outcomes (stunning and hibernation). J Cardiovasc Pharmacol. 1996;28(1 Suppl):S18–26
  11. Rahimtoola SH. Importance of diagnosing hibernating myocardium (how and in whom?). J Am Coll Cardiol. 1997;30:1701–1706
  12. Marin-Neto JA, Dilsizian V, Arrighi JA, et al.  Thallium scintigraphy compared with 18F-fluorodeoxyglucose positron emission tomography for assessing myocardial viability in patients with moderate versus severe left ventricular dysfunction. Am J Cardiol. 1998;82:1001–1007
  13. Ferrari R, Visioli O. Stunning (damaging or protective to the myocardium?). Cardiovasc Drugs Ther. 1991;5:939–945
  14. Sciagra R, Santoro GM, Bisi G, et al.  Rest-redistribution thallium-201 SPECT to detect myocardial viability. J Nucl Med. 1998;39:384–390
  15. Sciagra R, Bisi G, Santoro GM, et al.  Comparison of baseline-nitrate technetium-99m sestamibi with rest-redistribution thallium-201 tomography in detecting viable hibernating myocardium and predicting postrevascularization recovery. J Am Coll Cardiol. 1997;30:384–391
  16. Wintergreen Panel recommendations. J Nucl Cardiol 1998;6:93–155
  17. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. [erratum appears in Circulation 1993;87:2070] Circulation. 1993;87:1–20
  18. Bax JJ, Wijns W, Cornel JH, et al.  Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease (comparison of pooled data). J Am Coll Cardiol. 1997;30:1451–1460
  19. Maes AF, Borgers M, Flameng W, et al.  Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT (correlation with histologic and positron emission tomographic studies and functional follow-up). J Am Coll Cardiol. 1997;29:62–68
  20. Schwaiger M, Schricke U. Hibernating and stunned myocardium: pathophysiological considerations. In: Iskandrian AE, van der Wall, EE, editors. Myocardial viability. Dordrecht (The Netherlands): Kluwer Academic Publishers; 2000. p. 1–20
  21. Bisi G, Sciagra R, Santoro GM, et al.  Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates (feasibility and reliability for prediction of postrevascularization outcome of asynergic territories). J Am Coll Cardiol. 1994;24:1282–1289
  22. Gioia G, Milan E, Giubbini R, et al.  Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction. J Nucl Cardiol. 1996;3:150–156
  23. Allman KC, Shaw LJ, Hachamovitch R, et al.  Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction (a meta-analysis). J Am Coll Cardiol. 2002;39:1151–1158
  24. Iskander S, Iskandrian AE. Prognostic utility of myocardial viability assessment. Am J Cardiol. 1999;83:696–702
  25. Samady H, Elefteriades JA, Abbott BG, et al.  Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999;100:1298–1304
  26. Camici PG, Wijns W, Borgers M, et al.  Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation. 1997;96:3205–3214
  27. Vanoverschelde JL, Wijns W, Borgers M, et al.  Chronic myocardial hibernation in humans (from bedside to bench). Circulation. 1997;95:1961–1971
  28. Sciagra R, Pellegri M, Pupi A, et al.  Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2000;36:739–745
  29. Petretta M, Cuocolo A, Nicolai E, et al.  Combined assessment of left ventricular function and rest-redistribution regional myocardial thallium-201 activity for prognostic evaluation of patients with chronic coronary artery disease and left ventricular dysfunction. J Nucl Cardiol. 1998;5:378–386
  30. Petretta M, Cuocolo A, Bonaduce D, et al.  Incremental prognostic value of thallium reinjection after stress-redistribution imaging in patients with previous myocardial infarction and left ventricular dysfunction. J Nucl Med. 1997;38:195–200
  31. Gioia G, Powers J, Heo J, et al.  Prognostic value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardiol. 1995;75:759–762
  32. Cuocolo A, Petretta M, Nicolai E, et al.  Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging. Eur J Nucl Med. 1998;25:60–68
  33. Pagano D, Lewis ME, Townend JN, et al.  Coronary revascularisation for postischaemic heart failure (how myocardial viability affects survival). Heart. 1999;82:684–688
  34. Pagley PR, Beller GA, Watson DD, et al.  Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 1997;96:793–800
  35. Chan RK, Raman J, Lee KJ, et al.  Prediction of outcome after revascularization in patients with poor left ventricular function. Ann Thorac Surg. 1996;61:1428–1434
  36. Zhang X, Liu XJ, Wu Q, et al.  Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET. J Nucl Med. 2001;42:1166–1173
  37. Pasquet A, Robert A, D’Hondt AM, et al.  Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. [erratum appears in Circulation 1999;100:1584] Circulation. 1999;100:141–148
  38. Morse RW, Noe S, Caravalho J, et al.  Rest-redistribution 201-Tl single-photon emission CT imaging for determination of myocardial viability (relationship among viability, mode of therapy, and long-term prognosis). Chest. 1999;115:1621–1626
  39. Di Carli MF, Maddahi J, Rokhsar S, et al.  Long-term survival of patients with coronary artery disease and left ventricular dysfunction (implications for the role of myocardial viability assessment in management decisions). J Thorac Cardiovasc Surg. 1998;116:997–1004
  40. Eitzman D, al Aouar Z, Kanter HL, et al.  Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559–565
  41. Bourque J, Velazquez E, Borges-Neto S, et al.  A reappraisal of myocardial viability testing in patients with coronary artery disease and left ventricular dysfunction: can meta-analysis be trusted?. Heart Drug. 2002;2:204–205
  42. Antal EJ, Grasela THJ, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly. Clin Pharmacol Ther. 1989;46:552–559
  43. Montori VM, Smieja M, Guyatt GH. Publication bias (a brief review for clinicians). Mayo Clin Proc. 2000;75:1284–1288
  44. Shields PG. Publication bias is a scientific problem with adverse ethical outcomes (the case for a section for null results). Cancer Epidemiol Biomarkers Prev. 2000;9:771–772
  45. Cerqueira MD, Weissman NJ, Dilsizian V, et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart (a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association). Circulation. 1929;105:539–542
  46. Laupacis A, Wells G, Richardson WS, et al.  Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA. 1994;272:234–237
  47. Passamani E, Davis KB, Gillespie MJ, et al.  A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med. 1985;312:1665–1671
  48. Harrell FEJ. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer-Verlag; 2001;

    . p. 61.

  49. Hunt SA, Baker DW, Chin MH, et al.  ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult (a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)). J Am Coll Cardiol. 2001;38:2101–2113
  50. Bourque J, Velazquez E, Borges-Neto S, et al. Clinical characteristics and referral pattern of patients with left ventricular dysfunction and significant coronary artery disease undergoing radionuclide perfusion imaging. [abstract] J Nucl Cardiol 2002;98(1 Suppl):2:26

☆ Guest Editor for this manuscript was George A. Beller, MD, University of Virginia Health Sciences Center, Charlottesville, Va.Submitted May 13, 2002; accepted August 21, 2002.

PII: S0002-8703(02)94818-0

doi: 10.1016/S0002-8703(02)94818-0

American Heart Journal
Volume 145, Issue 5 , Pages 758-767 , May 2003

Article Tools

* Image Usage & Resolution